PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
ConditionProstate Cancer (Post Prostatectomy)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorAdventHealth
About this trial
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Eligibility criteria
Qualifiers
History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
Disqualifiers
Patients who are planned to have an x-ray contrast agent or other PET radiotracer & less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
Patients currently receiving Androgen Deprivation Therapy (ADT).
Trial design
Treatments tested in this trial
- 18F-rhPSMA-7.3 (Posluma)
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
AdventHealth
Lead sponsor
Blue Earth Diagnostics
Collaborator
Source ClinicalTrials.gov